A new CDC study examining the first decade of HIV antiretroviral therapy (ART) scale-up in Mozambique revealed fewer people are dying from HIV in recent years, likely due to more patients starting treatment at earlier disease stages. The analysis also found that people who more recently began ART were less likely to remain engaged in HIV treatment and care over time. The analysis highlights participation in community ART support groups (CASGs), small groups of patients who support each other to remain on ART, as an effective strategy to significantly reduce loss to follow up.
20 September 2016 | CDC
A new 2016 edition of MEDFASH's " HIV in Primary Care" has been published. An essential guide for GPs, practice nurses and other members of the primary healthcare team.
12 September 2016 | MEDFASH press release
With fewer than 10 weeks until the November general election, there is no shortage of topics for the presidential candidates to discuss and debate. On the health care front, the Kaiser Health Tracking Poll: August 2016 indicates that, though health-related concerns have largely taken a backseat in media coverage, a number of these issues -- including HIV -- are priorities for voting Americans.
12 September 2016 | The Body
The influential Health Select Committee has said a dispute with NHS England about HIV-preventing drugs has shown flaws in the government’s localised health legislation.
01 September 2016 | Pink News
Truvada, an expensive breakthrough drug that prevents people from getting HIV won't be funded by taxpayers in Australia this year, the nation's drug funding panel has ruled. A Department of Health spokeswoman said the PBAC understood "this is an important new prevention medication for HIV", but decided the price set by the drug's sponsor, Gilead Sciences, was too high and a proposal to limit subsidy to a small subset of the "at risk" group was not feasible.
"In its deliberations the PBAC indicated a substantial price reduction would be needed to make Truvada available for PrEP for the whole 'at risk' population, but noted that Truvada for PrEP could represent value for money in the broader population at a substantially lower price," the spokeswoman said.
19 August 2016 | Sydney Morning Herald
In pointed remarks, Germany’s cost-effectiveness watchdog has criticised an effort by European regulators to accelerate approval for new medicines by limiting its requirements for evidence. The concerns raised by the agency come as regulators on both side of the Atlantic increasingly look to such approaches to get new drugs to patients with unmet medical needs. At issue is a proposal called adaptive pathways, a term used to describe a method for jumpstarting drug approvals for select patient populations. Two years ago,an EMA pilot programme was launched to compare initial data used for approval with so-called “real world” data, which is subsequently gathered after the medicines are in use.
18 August 2016 | STAT
We’ve come a long way since the days when fighting for LGBT rights demanded action such as the Stonewall Riots. Or a critical need for HIV medications prompted protests blocking traffic on the Golden Gate Bridge. Are we finished? Have the communities and people affected by HIV and AIDS fought hard enough, and is the job of AIDS activists near an end?
16 August 2016 | BETA blog
Exclusive: The NHS is stopping participants in a major study into the drug Truvada from having further access to it – a move which Britain’s biggest HIV charity said would lead some to become infected.
29 July 2016 | Buzzfeed
The head of the UK’s largest HIV charity Terrence Higgins Trust was unfairly dismissed from her role, an employment tribunal has ruled. In 2014 Dr Rosemary Gillespie was appointed to reform the charity, which provides support services and campaigns on various issues related to AIDS and HIV. She was fired from the charity in July 2015, less than two years later.
29 July 2016 | Pink News
Gilead Sciences won a victory last week when a federal court judge tossed a lawsuit in which an AIDS activist group accused the drug maker of manipulating the patent system in order to thwart competition for its HIV medicines. At issue was tenofovir, or TDF, which Gilead is replacing with a modified version known as TAF.
13 July 2016 | STAT